Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

Rhea-AI Summary

Compass Therapeutics (Nasdaq: CMPX) will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. The presentation is scheduled for 7:30 AM PT and will be webcast at cmpx.info/jpmorgan.

Virtual replay and an archived copy will be available on Compass’ Events page. Compass is also hosting investor meetings as part of the LifeSci Partners Corporate Access Event on January 12–13, 2026 in San Francisco. Investors seeking one-on-one meetings should contact their J.P. Morgan or LifeSci representative to request meetings.

News Market Reaction

-5.34%

1 alert

-5.34% News Effect

On the day this news was published, CMPX declined 5.34%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

J.P. Morgan conference date: January 14, 2026 Presentation time: 7:30 AM PT LifeSci meetings start: January 12, 2026 +1 more

4 metrics

J.P. Morgan conference date January 14, 2026 J.P. Morgan 2026 Healthcare Conference presentation date

Presentation time 7:30 AM PT Scheduled J.P. Morgan presentation time

LifeSci meetings start January 12, 2026 LifeSci Partners Corporate Access Event meeting date

LifeSci meetings end January 13, 2026 LifeSci Partners Corporate Access Event meeting date

Market Reality Check

Price: $6.40 Vol: Volume 1,614,211 is at 0....

normal vol

$6.40 Last Close

Volume Volume 1,614,211 is at 0.88x the 20-day average. normal

Technical Price $5.24 is trading above the $3.11 200-day moving average.

Peers on Argus

Peers show mixed moves: TYRA up 1.82%, while XNCR, BCAX, ORKA, and VSTM are down...

Peers show mixed moves: TYRA up 1.82%, while XNCR, BCAX, ORKA, and VSTM are down between 0.24% and , suggesting CMPX’s move is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Nov 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 25	Investor conferences	Neutral	+1.2%	December 2025 healthcare investor conference participation and webcast availability.
Nov 05	Earnings and update	Positive	+0.8%	Q3 2025 financials with $220M cash and positive pipeline milestones.
Nov 04	Clinical data update	Positive	+1.3%	Preclinical CTX-10726 data showing strong anti-tumor activity and IND timing.
Nov 03	Investor conferences	Neutral	+0.0%	Participation in multiple November 2025 healthcare investor conferences.
Aug 26	Investor conferences	Neutral	+4.3%	September 2025 schedule of four major healthcare investor conferences.

Pattern Detected

Recent conference and investor event announcements have generally coincided with small positive or flat price moves, while clinical and earnings updates have also seen modest positive reactions.

Recent Company History

Over the last six months, Compass has frequently highlighted investor conference participation, with events on Sep, Nov, and Dec 2025 generally followed by modestly positive or flat price reactions. Alongside these, the company reported Q3 2025 results with $220 million in cash and meaningful pipeline updates across tovecimig, CTX-8371, and CTX-10726. Preclinical data for CTX-10726 and ongoing trial progress suggest a sustained clinical development focus. Today’s J.P. Morgan 2026 conference participation fits this pattern of active investor engagement alongside advancing oncology programs.

Market Pulse Summary

The stock moved -5.3% in the session following this news. A negative reaction despite neutral confer...

Analysis

The stock moved -5.3% in the session following this news. A negative reaction despite neutral conference news would contrast with prior investor event announcements, which historically saw flat to mildly positive moves, including a 1.21% gain and a 4.3% rise. Such a decline would likely reflect broader positioning or profit-taking rather than the event itself. Context includes CMPX trading above its $3.11 200-day moving average and recent clinical and financial disclosures shaping overall sentiment.

Key Terms

clinical-stage, oncology, biopharmaceutical, antibody-based therapeutics

4 terms

clinical-stage medical

"a clinical-stage, oncology-focused biopharmaceutical company developing proprietary"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

oncology medical

"a clinical-stage, oncology-focused biopharmaceutical company developing"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

biopharmaceutical medical

"oncology-focused biopharmaceutical company developing proprietary antibody-based"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

antibody-based therapeutics medical

"biopharmaceutical company developing proprietary antibody-based therapeutics, today announced"

Antibody-based therapeutics are medicines made from or modeled on antibodies, the proteins the immune system uses to recognize and attach to specific disease targets. Think of them as guided missiles that home in on a particular molecule on a virus, cancer cell or other harmful agent, which can improve effectiveness and reduce side effects. Investors watch them because they can command premium prices, carry patent value and regulatory risk, and often drive significant company growth or volatility depending on clinical and approval outcomes.

AI-generated analysis. Not financial advice.

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026.

Presentation Details
Date: Wednesday, January 14, 2026
Time: 7:30 AM PT
Webcast Link: cmpx.info/jpmorgan

Virtual/Replay availability: The presentation will be archived on Compass’ Events page.

Investors interested in scheduling one-on-one meetings with Compass on January 14, 2026 should contact their J.P. Morgan representative.

Compass will also host investor meetings as part of the LifeSci Partners Corporate Access Event, January 12 & 13, 2026 in San Francisco, CA. Interested investors should contact their LifeSci representative to request a meeting.  

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These pathways include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com 

Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com 
617-500-8099

FAQ

When will Compass Therapeutics (CMPX) present at the J.P. Morgan 2026 Healthcare Conference?

Compass will present on January 14, 2026 at 7:30 AM PT.

How can I watch the Compass Therapeutics (CMPX) presentation on January 14, 2026?

Watch the live webcast at cmpx.info/jpmorgan.

Will the Compass Therapeutics (CMPX) presentation be available after the conference?

Yes. The presentation will be archived and available on Compass’ Events page for replay.

How do investors schedule one-on-one meetings with Compass Therapeutics (CMPX) on January 14, 2026?

Investors should contact their J.P. Morgan representative to request one-on-one meetings.

When and where will Compass Therapeutics (CMPX) hold investor meetings with LifeSci Partners?

Compass will host meetings as part of the LifeSci Partners Corporate Access Event on January 12 and 13, 2026 in San Francisco; contact your LifeSci representative to request a meeting.